Latest News
VIRALEZE COVID-19 nasal spray study to commence in January
Dec 22nd, 2020
Starpharma today announced that it has received all necessary approvals to commence its clinical study for VIRALEZE™. The study will commence enrolment of healthy volunteers in Perth in early January 2021 and is expected to be completed in Q1 2021. This study is being undertaken to support commercialisation activities for VIRALEZE™, and is not a requirement to achieve EU product registration.
Read MoreVIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21
Dec 10th, 2020
Starpharma today announced significant commercial and regulatory progress has been made for VIRALEZE™ nasal spray with the EU regulatory dossier more than 90% complete and VIRALEZE™ now on track to be registered, and ready for market in Q1 CY2021. This timing is earlier than previously announced.
Read MoreAGM Chairman address and CEO presentation
Nov 20th, 2020
Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.
Read More
SPL7013 shows potent antiviral activity in RSV expanding use for nasal spray
Nov 19th, 2020
Starpharma today announced it has completed additional testing showing potent antiviral activity of SPL7013 against human respiratory syncytial virus (RSV). RSV is a common and very contagious virus that affects the lungs and airways. RSV is most problematic in the young and the elderly and those with weakened immune systems, or chronic heart and lung disease, including asthma. More than 177,000 adults are hospitalized and 14,000 of them die due to RSV infection in the US annually. RSV is also one of the viruses responsible for the common cold.
Read More